Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adolescents and Young Adults With AML

How do their outcomes compare with their elders?

Publish date:: January 13, 2016

Outcomes for adolescent and young adult (AYA) patients with acute myeloid leukemia (AML) are overall better than for older adults with AML, according to a study of 3,922 adult patients with AML, including 432 aged 16 to 29 years. Researchers found that in the AYA group:

• 17% of patients had Core Binding Factor (CBF) AML and 12% had acute promyelocytic leukemia (APL).

• Complete remission (CR) rates were 93% for CBF AML, 78% for APL, 77% for diploid karyotype, and 68% for other AML.

• Univariate analysis demonstrated higher rates of CR, CR duration, and overall survival vs older patients.

• On multivariate analysis, AYA age group was independently associated improved CR rate and CR duration, with a trend toward longer overall survival.

Citation: Pemmaraju N, Kantarjian H, Ravandi F, et al. Patient characteristics and outcomes in adolescents and young adults (AYA) with acute myeloid leukemia (AML). [Published online ahead of print January 5, 2016]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2015.12.010.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,